Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
48 hedge funds and large institutions have $18.8M invested in Aptose Biosciences, Inc. in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 9 closing their positions.
2,533% more call options, than puts
Call options by funds: $158K | Put options by funds: $6K
8% less funds holding
Funds holding: 52 → 48 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
52% less capital invested
Capital invested by funds: $39M → $18.8M (-$20.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
+$365K |
| 2 |
AC
Annandale Capital
Dallas,
Texas
|
+$203K |
| 3 |
VC
Voss Capital
Houston,
Texas
|
+$160K |
| 4 |
Morgan Stanley
New York
|
+$85.6K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$54.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$1.4M |
| 2 |
Millennium Management
New York
|
-$669K |
| 3 |
Renaissance Technologies
New York
|
-$574K |
| 4 |
Two Sigma Investments
New York
|
-$387K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$366K |
APTO Hedge Fund Activity: Q2 2022 in Review
48 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q2 2022, worth a combined $18.8M — down 52% from $39M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of APTO and 5 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Carlson Capital, adding an estimated $365K. The largest seller was Sanders Morris Harris, cutting an estimated $1.4M.
- 48 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q2 2022, down from 52 in Q1 2022.
- Funds reported $18.8M of Aptose Biosciences, Inc. stock for Q2 2022, down 52% quarter-over-quarter.
- 5 funds opened new Aptose Biosciences, Inc. positions in Q2 2022 and 9 closed out, a net change of -4 holders.
- The largest Aptose Biosciences, Inc. buyer in Q2 2022 was Carlson Capital, an estimated $365K added.
- The largest Aptose Biosciences, Inc. seller in Q2 2022 was Sanders Morris Harris, an estimated $1.4M sold.
Based on aggregated 13F filings for Q2 2022.